Literature DB >> 15006899

Modulation of trigeminal sensory neuron activity by the dual cannabinoid-vanilloid agonists anandamide, N-arachidonoyl-dopamine and arachidonyl-2-chloroethylamide.

Theodore J Price1, Amol Patwardhan, Armen N Akopian, Kenneth M Hargreaves, Christopher M Flores.   

Abstract

1. Peripheral cannabinoids have been shown to suppress nociceptive neurotransmission in a number of behavioral and neurophysiological studies. It is not known, however, whether cannabinoids exert this action through direct interactions with nociceptors in the periphery and/or if other processes are involved. To gain a better understanding of the direct actions of cannabinoid-vanilloid agonists on sensory neurons, we examined the effects of these compounds on trigeminal ganglion (TG) neurons in vitro. 2. AEA (EC(50)=11.0 microM), NADA (EC(50)=857 nM) and arachidonyl-2-chloroethylamide ACEA (EC(50)=14.0 microM) each evoked calcitonin gene-related peptide (CGRP) release from TG neurons. The TRPV1 antagonists iodo-resiniferatoxin (I-RTX) and capsazepine (CPZ) each obtunded AEA-, NADA-, ACEA- and capsaicin (CAP)-evoked CGRP release with individually equivalent IC(50)'s for each of the compounds (I-RTX IC(50) range=2.6-4.0 nM; CPZ IC(50) range=523-1140 microM). 3. The pro-inflammatory mediator prostaglandin E(2) significantly increased the maximal effect of AEA-evoked CGRP release without altering the EC(50). AEA, ACEA and CAP stimulated cAMP accumulation in TG neurons in a calcium- and TRPV1-dependent fashion. Moreover, the protein kinase inhibitor staurosporine significantly inhibited AEA- and CAP-evoked CGRP release. 4. The pungency of AEA, NADA, ACEA and CAP in the rat eye-wipe assay was also assessed. Interestingly, when applied intraocularly, NADA or CAP each produced nocifensive responses, while AEA or ACEA did not. 5. Finally, the potential inhibitory effects of these cannabinoids on TG nociceptors were evaluated. Neither AEA nor ACEA decreased CAP-evoked CGRP release. Furthermore, neither of the cannabinoid receptor type 1 antagonists SR141716A nor AM251 had any impact on either basal or CAP-evoked CGRP release. AEA also did not inhibit 50 mM K(+)-evoked CGRP release and did not influence bradykinin-stimulated inositol phosphate accumulation. 6. We conclude that the major action of AEA, NADA and ACEA on TG neurons is excitatory, while, of these, only NADA is pungent. These findings are discussed in relation to our current understanding of interactions between the cannabinoid and vanilloid systems and nociceptive processing in the periphery.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15006899      PMCID: PMC1574881          DOI: 10.1038/sj.bjp.0705711

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  71 in total

1.  Developmental alterations in nociceptive threshold, immunoreactive calcitonin gene-related peptide and substance P, and fluoride-resistant acid phosphatase in neonatally capsaicin-treated rats.

Authors:  D L Hammond; M A Ruda
Journal:  J Comp Neurol       Date:  1991-10-15       Impact factor: 3.215

2.  Alleviation of mechanical and thermal allodynia by CGRP(8-37) in a rodent model of chronic central pain.

Authors:  A D Bennett; K M Chastain; C E Hulsebosch
Journal:  Pain       Date:  2000-05       Impact factor: 6.961

3.  Structural and functional specialization of A delta and C fiber free nerve endings innervating rabbit corneal epithelium.

Authors:  M B MacIver; D L Tanelian
Journal:  J Neurosci       Date:  1993-10       Impact factor: 6.167

4.  Actions of cannabinoid receptor ligands on rat cultured sensory neurones: implications for antinociception.

Authors:  R A Ross; A A Coutts; S M McFarlane; S Anavi-Goffer; A J Irving; R G Pertwee; D J MacEwan; R H Scott
Journal:  Neuropharmacology       Date:  2001       Impact factor: 5.250

5.  In vivo pharmacology of SDZ 249-665, a novel, non-pungent capsaicin analogue.

Authors:  Laszlo Urban; Elizabeth A Campbell; Moh Panesar; Sadhana Patel; Naureen Chaudhry; Steven Kane; Karl-Heinz Buchheit; Barrie Sandells; Iain F James
Journal:  Pain       Date:  2000-12-15       Impact factor: 6.961

6.  Structure of a cannabinoid receptor and functional expression of the cloned cDNA.

Authors:  L A Matsuda; S J Lolait; M J Brownstein; A C Young; T I Bonner
Journal:  Nature       Date:  1990-08-09       Impact factor: 49.962

7.  Capsaicin-induced ion fluxes increase cyclic GMP but not cyclic AMP levels in rat sensory neurones in culture.

Authors:  J N Wood; P R Coote; A Minhas; I Mullaney; M McNeill; G M Burgess
Journal:  J Neurochem       Date:  1989-10       Impact factor: 5.372

8.  Molecular characterization of a peripheral receptor for cannabinoids.

Authors:  S Munro; K L Thomas; M Abu-Shaar
Journal:  Nature       Date:  1993-09-02       Impact factor: 49.962

9.  Signal transduction differences between 5-hydroxytryptamine type 2A and type 2C receptor systems.

Authors:  K A Berg; W P Clarke; C Sailstad; A Saltzman; S Maayani
Journal:  Mol Pharmacol       Date:  1994-09       Impact factor: 4.436

10.  Endothelin-1 enhances capsaicin-induced peptide release and cGMP accumulation in cultures of rat sensory neurons.

Authors:  J Dymshitz; M R Vasko
Journal:  Neurosci Lett       Date:  1994-02-14       Impact factor: 3.046

View more
  67 in total

1.  Opposing roles for cannabinoid receptor type-1 (CB₁) and transient receptor potential vanilloid type-1 channel (TRPV1) on the modulation of panic-like responses in rats.

Authors:  Plínio C Casarotto; Ana Luisa B Terzian; Daniele C Aguiar; Hélio Zangrossi; Francisco S Guimarães; Carsten T Wotjak; Fabrício A Moreira
Journal:  Neuropsychopharmacology       Date:  2011-09-21       Impact factor: 7.853

Review 2.  [Cannabinoids--signal transduction and mode of action].

Authors:  R Rukwied; B Gauter; M Schley; C Konrad
Journal:  Schmerz       Date:  2005-11       Impact factor: 1.107

3.  Differences in peripheral endocannabinoid modulation of scratching behavior in facial vs. spinally-innervated skin.

Authors:  Jessica Marie Spradley; Auva Davoodi; Leland Bruce Gee; Mirela Iodi Carstens; E Carstens
Journal:  Neuropharmacology       Date:  2012-06-06       Impact factor: 5.250

Review 4.  International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂.

Authors:  R G Pertwee; A C Howlett; M E Abood; S P H Alexander; V Di Marzo; M R Elphick; P J Greasley; H S Hansen; G Kunos; K Mackie; R Mechoulam; R A Ross
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

Review 5.  The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids.

Authors:  Roger G Pertwee
Journal:  AAPS J       Date:  2005-10-24       Impact factor: 4.009

Review 6.  Endocannabinoids and immune regulation.

Authors:  Rupal Pandey; Khalida Mousawy; Mitzi Nagarkatti; Prakash Nagarkatti
Journal:  Pharmacol Res       Date:  2009-04-07       Impact factor: 7.658

Review 7.  Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors.

Authors:  Antonia Serrano; Loren H Parsons
Journal:  Pharmacol Ther       Date:  2011-07-18       Impact factor: 12.310

Review 8.  TRPV1: on the road to pain relief.

Authors:  Andrés Jara-Oseguera; Sidney A Simon; Tamara Rosenbaum
Journal:  Curr Mol Pharmacol       Date:  2008-11       Impact factor: 3.339

Review 9.  Role of ionotropic cannabinoid receptors in peripheral antinociception and antihyperalgesia.

Authors:  Armen N Akopian; Nikita B Ruparel; Nathaniel A Jeske; Amol Patwardhan; Kenneth M Hargreaves
Journal:  Trends Pharmacol Sci       Date:  2008-12-11       Impact factor: 14.819

10.  Properties of the inner pore region of TRPV1 channels revealed by block with quaternary ammoniums.

Authors:  Andrés Jara-Oseguera; Itzel Llorente; Tamara Rosenbaum; León D Islas
Journal:  J Gen Physiol       Date:  2008-11       Impact factor: 4.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.